Another study compared the effect of two standard NSCLC drugs gemcitabine (chemotherapy), and gefitinib (an EGFR TKI), on NKG2D ligand expression and NK cell activity [49]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.